Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 11/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19880454 | 0.83 | PDE4D (0.49) | PDE4DPDE4BMAPTPDE4APDE4C | |
| SCHEMBL19779519 | 0.82 | PDE4D (0.43) | PDE4DPDE4BMAPTPDE4APDE4C | |
| SCHEMBL19780240 | 0.81 | PDE4D (0.36) | PDE4DPDE4BMAPTPDE4APDE4C | |
| SCHEMBL22096869 | 0.81 | PDE4D (0.42) | PDE4DPDE4BMAPTPDE4APDE4C | |
| SCHEMBL19779455 | 0.81 | MAPT (0.44) | PDE4DPDE4BMAPTPDE4APDE4C | |
| SCHEMBL19779457 | 0.76 | PDE4D (0.47) | PDE4DPDE4BMAPTPDE4APDE4C | |
| SCHEMBL28318216 | 0.68 | ATM (0.44) | PDE4DMAPT | |
| SCHEMBL21883563 | 0.67 | NAMPT (0.36) | PDE4DPDE4BPDE4APDE4CCDK5 | |
| SCHEMBL2830918 | 0.66 | PDE4D (0.47) | PDE4DPDE4BMAPTPDE4APDE4C | |
| SCHEMBL71356 | 0.66 | PDE4D (0.47) | PDE4DPDE4BMAPTPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021076448-A1 | SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-10351547-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2019-01-03 | — | — | US | disclosed |
| WO-2018013676-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351547-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | PDE4D 117/4885PDE4B 113/4885MAPT 3109/4885 |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | PDE4D 117/4885PDE4B 113/4885MAPT 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.